Acute promyelocytic leukemia(APL) is a subtype of AML. What are leukemia causes and risk factors? The exact cause of leukemia is not known, but it is thought to involve a combination of genetic and environmental factors. Leukemia cells have acquired mutations in their DNA that cause them to ...
With further consolidation chemotherapy without high-dose cytosine arabinoside, the disease-free survival rate can reach 70% to 80%, and many of these patients are cured, more so than in any other AML subtype. APL is especially sensitive to anthracyclines, which should be included in the ...
ATO was first utilized in APL patients in the early 1990s, and led to a high CR rate with relatively long-term remissions when used as a single agent.48In preclinical models, the combination of ATRA and ATO demonstrated synergism in inducing differentiation and apoptosis,49,50,51allowing for ...
What is the survival rate for AML? This is tough to answer because there are many different types of AML, and each type has differences in treatment options and survival rates. In general: People younger than 65 usually fare better than older people. People with certain genetic mutations tend...
This treatment strategy results in a high complete remission (CR) rate of about 90% and an overall survival rate of 80%. About 5%–30% of patients relapse, mainly patients with high-risk APL. Relapse at extramedullary sites, which occurs in approximately 3%–5% of patients, is emerging as...
Among patients who tolerated four courses on the FLAG-IDA arm (2 FLAG-IDA + 2 high-dose cytarabine), the 8-year survival rate was 66% versus 47% in the standard arm15,87,98. The FLAG-IDA/FAI is intensive and difficult to deliver due to side effects related to myelosuppression, ...
Subsequently, the differentiation induction therapy with ATRA and ATO has strikingly improved the clinical outcome of APL patients, and its long-term survival rate is ≥95%, but there are still 5% of patients dead of refractory/relapsed disease [2,3,4]. In detail, these refractory/relapsed ...
A Population-Based Study In Acute Promyelocytic Leukemia (APL) Suggests a Higher Early Death Rate and Lower Overall Survival Than Commonly Reported In Clinical Trials: Data From the Surveillance, Epidemiology, and End Results (SEER) Prog... 872Background:All-trans retinoic acid (ATRA) with contem...
Overall survival (OS) was very poor; i-ALL patients reached ∼41% in 5-year survival, whereas in i-AML the survival rate was ∼26%. Unfortunately, we have not adequately improved therapy and effective supportive care to increase the survival rates of CL (21). Because of the very low...
et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J. Natl. Cancer Inst. 90, 850–858 (1998). 11. Hasford, J. et al. Predicting complete cytogenetic ...